Global Non-invasive Prenatal Testing Market, By Product and Services (Products, Services), Method (Ultrasound Detection, Biochemical Screening Test, Cell-Free DNA in Maternal Plasma Tests), Application (Trisomy, Microdeletion Syndrome, Other), End-User (Diagnostic Laboratories, Hospitals), Test Type (Materni21, Harmony, Panorama, Verify, NIFTY, Others), Technology (NGS, WGS, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
After introducing next-generation sequencing technology, it is now possible to sequence foetal DNA fragments that can be built into a whole genetic map, allowing the foetal genome to be inspected prenatally and non-invasively. Novel screening approaches for foetal chromosomal aneuploidies have been developed as a result of advances in molecular technologies and the identification of cell-free foetal DNA in maternal plasma.
Data Bridge Market Research analyses that the non-invasive prenatal testing market which was USD 3.22 billion in 2021, would rocket up to USD 9.06 billion by 2029, and is expected to undergo a CAGR of 13.80% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Product and Services (Products, Services), Method (Ultrasound Detection, Biochemical Screening Test, Cell-Free DNA in Maternal Plasma Tests), Application (Trisomy, Microdeletion Syndrome, Other), End- User (Diagnostic Laboratories, Hospitals), Test Type (Materni21, Harmony, Panorama, Verify, NIFTY, Others), Technology (NGS, WGS, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Illumina, Inc. (U.S), Thermo Fisher Scientific Inc. (U.S), General Electric (U.S), BGI Group (China), Agilent Technologies, Inc. (U.S), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (U.S), Laboratory Corporation of America Holdings (U.S), Natera, Inc. (U.S), Yourgene Health (U.S), Eurofins LifeCodexx GmbH (Germany), Quest Diagnostics Incorporated (U.S), Myriad Genetics Inc. (U.S), NIPD Genetics (Cyprus), Next Biosciences (South Africa)
Non-invasive prenatal testing is a DNA-based blood test that is used to assess the risk of genetic disorders in the developing foetus. This is done to see if you have Down syndrome, Patau syndrome, or Edwards syndrome, among other things.
Non-invasive Prenatal Testing Market Dynamics
- High risk of chromosomal abnormalities with increasing maternal age
The age of a woman at the time of delivery is referred to as her maternal age. Increasing maternal age can lead to a variety of health issues, including reduced fertility, high blood pressure, and an increased chance of miscarriage, stillbirths, and maternal mortality. Furthermore, as a result of faulty chromosomal division, maternal age can raise the incidence of genetic abnormalities in newborns. Microcephaly, a short neck, upward slanted eyes, weak muscular tone, and heart, intestinal, and breathing difficulties are all possible outcomes in neonates. These data imply that there has been an increase in maternal advanced age over the world, which is likely to lead to more health issues. Thus, the increasing maternal age, coupled with the increasing incidence of chromosomal abnormalities, is expected to drive the demand for NIPT tests.
- Growing incidence of chromosomal abnormalities
The rising frequency of chromosomal abnormalities, as well as increased product utilisation in new applications, are driving the market's organic revenue growth. Furthermore, innovations in existing tests in terms of expanded functionality, improved chemistry, and bioinformatics analysis are projected to drive market growth. The improvement of payment policies for ordinary and low-risk pregnancies is one of the market's primary driving forces. Natera announced in December 2020 that its non-invasive prenatal testing (NIPT) would be covered for all pregnancies by Aetna, the leading U.S. health insurer.
- High incidence rate of down syndrome
One of the key factors driving the market for non-invasive prenatal testing (NIPT) is the rise in average maternal age, which has raised concerns about the fetus's safety. Down syndrome is a chromosomal disorder in which an extra chromosome 21 is formed as a result of a cell division error, and it can damage a foetus' cognitive abilities and physical growth. The NIPT screening tests are safe for both the mother and the baby, pose no risk of miscarriage, and can detect more than 99 percent of Down syndrome instances. According to the National Down Syndrome Society and the Centers for Disease Control and Prevention, one out of every 700 babies in the United States is born with Down syndrome, and 80 percent of Down syndrome children are born to older moms. The increased risk of having babies with Down syndrome among older women drives the non-invasive prenatal testing market.
NIPT can be used to detect chromosomal abnormalities such as Down syndrome, trisomy 18 and 13, as well as excess or missing X or Y chromosomes. The likelihood of a genetic disease in the foetus is determined via non-invasive prenatal examinations. The market for non-invasive prenatal testing is being driven by an increase in the number of kids with chromosomal disorders and improved diagnostic imaging technology. Growing insurance coverage for average and low-risk pregnancies is also expected to have a benefit the non-invasive prenatal testing market.
- Reliability of test results, especially in obese women
NIPT tests are available to patients between the ages of 10 and 20 weeks of pregnancy. These tests need the extraction of foetal DNA from maternal blood in order to determine chromosomal abnormalities. The mother makes up the majority of cell-free DNA circulating in maternal blood, with only 10-15 percent coming from the foetus. The amount of foetal fraction in the blood is influenced by a variety of circumstances. Maternal weight, for instance, has a significant impact on the amount of foetal fraction in maternal blood. Low quantities of foetal DNA in the plasma of obese women can lead to erroneous results when testing for trisomy and other disorders.
Patients who weigh more than 250 pounds may experience unclear outcomes as a result, NIPT cannot detect chromosomal abnormalities in obese women. Furthermore, positive NIPT results may demand invasive confirmation tests such as amniocentesis and CVS. This poses a significant threat to the non-invasive prenatal testing market expansion.
This non-invasive prenatal testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-invasive prenatal testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Non-invasive Prenatal Testing Market
Though the COVID-19 pandemic continues to alter the growth of numerous markets, the outbreak's immediate impact is diverse. Due to the suspension of non-invasive prenatal screening (NIPS) services to limit the spread of the COVID-19 virus, the outbreak is projected to have an impact on the non-invasive prenatal testing (NIPT) industry. In reality, one of the obstacles preventing hospitals and diagnostic centres from delivering non-invasive prenatal screening (NIPS) services is the great demand on hospitals to give treatments to COVID-19 patients. The COVID quarantine has also brought NIPT to the forefront, as it provides high-accuracy screening with a low risk of infection, as opposed to invasive procedures like amniocentesis and chorionic villus sampling (CVS), both of which may require hospitalisation and expose both doctors and patients to the COVID virus. As a result of the present lockdown, there has been a surge in the prescription of NIPTs. The causes could be complex; during the lockdown, the number of elective treatments in hospitals decreased, and patients may have been hesitant to have procedures for fear of contracting COVID.
- In January 2022, In order to deliver non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR business, QIAGEN formed partnerships with Atila BioSystems.
- In June 2021, Next-generation genomics and Illumina Thailand has launched the VeriSeq NIPT Solution v2, a next-generation sequencing (NGS)-based solution that helps detect anomalies missed by targeted tests.
Global Non-invasive Prenatal Testing Market Scope
The non-invasive prenatal testing market is segmented on the basis of product, method, application, test type, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Assay Kits and Reagents
- NGS Systems
- PCR Instruments
- Ultrasound Devices
- Other Instruments
Biochemical Screening Tests
Cell-free DNA in Maternal Plasma Tests
- Microdeletion Syndrome
- Other Applications
- Diagnostic Laboratories
Non-invasive Prenatal Testing Market Regional Analysis/Insights
The non-invasive prenatal testing market is analysed and market size insights and trends are provided by country, product, method, application, test type, technology and end-user as referenced above.
The countries covered in the non-invasive prenatal testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the largest share for non-invasive prenatal testing market in the forecast period of 2022 to 2029.
Asia-Pacific is expected to have the highest CAGR due to development in the healthcare infrastructure and increasing awareness programs for NIPT.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Non-invasive Prenatal Testing Market Share Analysis
The non-invasive prenatal testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non-invasive prenatal testing market.
Some of the major players operating in the non-invasive prenatal testing market are:
- Illumina, Inc. (U.S)
- Thermo Fisher Scientific Inc. (U.S)
- General Electric (U.S)
- BGI Group (China)
- Agilent Technologies, Inc. (U.S)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- PerkinElmer Inc. (U.S)
- Laboratory Corporation of America Holdings (U.S)
- Natera, Inc. (U.S)
- Yourgene Health (U.S)
- Eurofins LifeCodexx GmbH (Germany)
- Quest Diagnostics Incorporated (U.S)
- Myriad Genetics Inc. (U.S)
- NIPD Genetics (Cyprus)
- Next Biosciences (South Africa)